The oil price drop is coming to a head within the next few months before the Linn hedges expire. But the outcome is unsure. Will OPEC + Russia agree on quotas that all the players hold to or will everyone keep producing and we have low oil prices for the next few years ?
The market cap of all of ECYT is only $139 million , That's pocket change to a company like Merck or Lilly.
If any big company realizes that 1456 is going to be a good drug ECYT will be bought out.
There is no way that a company with 57 employees ( some doing lab work) needs 26,000 sq. ft.
Is it possible that 26K is the minimum amount that WTC would lease out. PGNX might keep only 3-5 K and sub lease the rest to other small companies ?
Tie up with a Chinese company and send some of the surplus rigs to China to drill for shale gas. China needs to replace their coal fired energy and they have lots of shale rock to drill i.
This company does have some good properties. Maybe a large international oil company will try to buy CHK on the cheap say $9.00 share. There will not be enough shares available to cover the short position.
Pull the trigger at some point when they are sure the heart drug is good enough to get FDA approval. Remember, Amgen paid 10 billion for ONYX whose products were for a much smaller number of patients.
Wait until the kidney drug gets approved. One of these days the shorts will figure out that the stock is headed up not down. Maybe a buyout from Roche will do the trick.
Back in 2008 BMY and EXEL signed a partnership for several EXEL drugs that included XL184 which is now known as Cabzantinib. In May 2010 during one of it's cost cutting moves, BMY gave XL184 back to EXEL. In Nov. 2010 EXEL and BMY researchers reported good data for XL184 at a big cancer meeting in Europe. On July 13, 2015 it was announced that NCI is starting a big new trial in GU and kidney cancer using a combination of Cabo and Opdivo. Opdivo is BMY's immunotherapy drug that is doing very well. The BMY- EXEL connection is alive and well.